Fig. 3.

Withanolide E enhances death receptor-induced apoptosis in vivo [reproduced from [28]] . Athymic nude mice were injected subcutaneously with 1 × 10⁶ ACHN cells. When tumors reached approximately 100 mm³ in diameter, mice were randomly assigned into four groups for therapy. Mice were treated with either vehicle control, withanolide E (20 mg/kg), DR5 agonist antibody; drozitumab (5 mg/kg) or the combination of withanolide E plus drozitumab twice weekly for 4 weeks as described in (27). a Tumor size at 75 days (intratumor), b survival up to 150 days (intraperitoneal)—pooled from two separate experiments with similar findings. Numbers of mice were as follows: vehicle control (n = 10), withanolide E (n = 10), drozitumab (n = 14), and withanolide E plus drozitumab (n = 16). Using the log-rank Mantel–Cox test, survival was significantly higher in the group receiving the withanolide E plus drozitumab combination (p < 0.05)